Search Product
Structure Search
Search
Online Support
-
Customer service
Advantage Products
Location: Technique Support
比较唑来膦酸与利塞膦酸（105462-24-6）在激素诱导的骨质疏松中的疗效
2014-08-27
来源：亚科官网
亚科化学试剂带领大家比较唑来膦酸与利塞膦酸（105462-24-6）在激素诱导的骨质疏松中的疗效：
方法 选取本院2007年1月至2010年1月糖皮质激素诱导的骨质疏松患者120例,随机双盲试验,分为唑来膦酸组60例,利塞膦酸组60例,疗程均为连续治疗12个月.比较两组患者的骨密度及血清β-CTx及骨形成标志物P1NP浓度等指标.结果 唑来膦酸组患者治疗后血清β-CTx浓度远低于利塞膦酸组患者血清浓度(P＜0.05).结论 唑来膦酸静脉滴注能够显著增加腰椎及股骨颈骨密度基值,降低β-CTx及P1NP血清浓度,治疗效果远优胜于利塞膦酸.
作者 ： 陈根强[1] 许慧娟[1] 马华鹰[2] 汪志明[2]
Author： Chen Genqiang[1] Xu Huijuan[1] Ma Huaying[2] Wang Zhiming[2]
作者单位 ：
金华职业技术学院医学院,浙江金华,321000
浙江省金华市中心医院,321000
刊 名： 重庆医学 ISTICPKU
Journal： CHONGQING MEDICINE
年，卷(期) ： 2013, 42(8)
关键词： 骨质疏松/治疗 知识脉络 唑来膦酸 知识脉络 利塞膦酸 知识脉络
机标分类号 ： S82 S65
在线出版日期 ： 2013年4月9日
参考文献(15条)
van Staa TP,Leufkens HG,Abenhaim L. Use of oral corticosteroids and risk of fractures[J].Journal of Bone and Mineral Research,2009,(12):993-1000.
Boonen S,Lorenc RS,Orwoll ES. Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment:results from the 2-year,open-label,extension study of a 2-year,randomized,double-blind,placebo-controlled study[J].Bone,2012,(03):383-388.
van Staa TP,Leufkens HG,Abenhaim L. Oral corticosteroids and fracture risk:relationship to daily and cumulative doses[J].Rheumatology(Oxford),2000,(12):1383-1389.
Dissette V,Bozzi B,Pasti L. Particulate adducts based on sodium risedronate and titanium dioxide for the bioavailability enhancement of oral administered bisphosphonates[J].European Journal of Pharmaceutical Sciences,2010,(02):328-336.
The digitalis investigation group. American college of rheumatology Ad Hoc committee on glucocorticoid-induced osteoporosis.Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis:2001 update[J].Arthritis and Rheumatism,2001,(16):1496-1503.
Watts NB,Brown JP,Cline G. Risedronate on 2 consecutive days a month reduced vertebral fracture risk at 1 year compared with historical placebo[J].Journal of Clinical Densitometry,2010,(01):56-62.
Devogelaer JP,Goemaere S,Boonen S. Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis:a consensus document of the Belgian Bone Club[J].Osteoporosis International,2006,(01):8-19.
van Staa TP. The pathogenesis,epidemiology and management of glucocorticoid-induced osteoporosis[J].Calcified Tissue International,2006,(02):129-137.
Carbonell-Abella C,Gua?abens-Gay N,Marín-Rives JA. Analysis of therapeutic compliance in women with osteoporosis[J].Reumatología Clínica,2011,(05):299-304.
Cohen S,Levy RM,Keller M. Risedronate therapy prevents corticosteroid-induced bone loss:a twelve-month,multicenter,randomized,double-blind,placebo-controlled,parallel-group study[J].Arthritis and Rheumatism,1999,(11):2309-2318.
技术支持：苏州亚科化学试剂 http://www.yacoo.com.cn/
